Related references
Note: Only part of the references are listed.The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers
S. El Messaoudi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults
Yoshinobu Nakamaru et al.
CLINICAL THERAPEUTICS (2015)
SLC47A1 gene rs2289669 G > A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients
Rui He et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers
Mette Marie Hougaard Christensen et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats
Frank A. Duca et al.
NATURE MEDICINE (2015)
A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes
Ivan Tkac et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers
Sung Kweon Cho et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Genetic Variants in Transcription Factors Are Associated With the Pharmacokinetics and Pharmacodynamics of Metformin
S. Goswami et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Influences of Organic Cation Transporter Polymorphisms on the Population Pharmacokinetics of Metformin in Healthy Subjects
Hwa Yoon et al.
AAPS JOURNAL (2013)
Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes
I. Tkac et al.
DIABETES OBESITY & METABOLISM (2013)
Functional characterization of MATE2-K genetic variants and their effects on metformin pharmacokinetics
Jae-Yong Chung et al.
PHARMACOGENETICS AND GENOMICS (2013)
Clinical Pharmacokinetics of Metformin
Garry G. Graham et al.
CLINICAL PHARMACOKINETICS (2011)
Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus
Ying Hong et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care
M. N. Cook et al.
DIABETIC MEDICINE (2007)
Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: A single-center, multiple-dose, open-label study
N Rao et al.
CLINICAL THERAPEUTICS (2005)
Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers
SH Lee et al.
ARCHIVES OF PHARMACAL RESEARCH (2004)
Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect
D Stepensky et al.
DRUG METABOLISM AND DISPOSITION (2002)
Share Paper
